Urbach Tanya Durkee 4

4 · CytoDyn Inc. · Filed Mar 24, 2026

AI-generated summary of this filing

Updated Mar 24, 2026

CytoDyn (CYDY) Director Tanya Durkee Receives Award

What Happened

Tanya Durkee, a director of CytoDyn Inc. (CYDY), was granted an equity award reported as a derivative acquisition of 574,385 shares on March 20, 2026. The filing shows an acquisition price of $0.00 per share (derivative security), i.e., no cash paid at grant.

Key Details

Transaction date: 2026-03-20; filing date (Form 4): 2026-03-24 (filed within the required two business days).
Transaction type/code: A = Award/Grant (derivative security).
Shares/units granted: 574,385 (reported at $0.00 per share in the filing).
Ownership after transaction: Not specified in the public Form 4 excerpt provided.
Notable footnotes:
- F1: Grant approved by the Compensation Committee on March 20, 2026; annual grant under the Issuer’s 2012 Equity Incentive Plan (shares reserved under the plan).
- F2: The award is structured as a stock option that will vest in approximately 12 equal monthly installments from April 2026 through March 2027.
Timeliness: Filing appears timely (not marked late).

Context

This was an equity award (derivative/option) to a director as part of routine compensation—common for board members and consistent with the company’s stated annual grant practice. Such awards are standard compensation and do not, by themselves, indicate buy/sell sentiment; vesting schedule means economic benefit is realized over the coming year.

Form 4

Period: 2026-03-20

Director

Transactions

Award
Non-qualified stock option (right to buy)
[F1][F2]
2026-03-20+574,385→ 574,385 total
Exercise: $0.28Exp: 2036-03-20→ Common Stock (574,385 underlying)

Footnotes (2)

[F1]This grant was approved by the Company's Compensation Committee on March 20, 2026, and represents the annual grant to the individual for fiscal year 2026 consistent with past practice in recent years. This award was made in compliance with, and uses shares that are specifically reserved for issuance to employees, directors, and certain outside consultants under, the Issuer's 2012 Equity Incentive Plan, as amended (the "2012 Plan").
[F2]The stock option will vest in 12 approximately equal installments on the same day of each month of Continuous Service (as the term is defined in the 2012 Plan) beginning April 2026 through March 2027.

Signature

/s/ Tyler Blok, Attorney-in-Fact for Tanya Durkee Urbach|2026-03-24

1 file